文献速递糖尿病

度拉糖肽与2型糖尿病肾脏功能相关结局:REWIND试验的事后分析

Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
PubMed 文献 · Diabetes Care · 2023-01-01

REWIND试验事后分析纳入度拉糖肽1.5 mg组4949例与安慰剂组4952例2型糖尿病伴心血管疾病或危险因素者,肾脏功能相关复合结局(eGFR持续下降≥40%、终末期肾病或肾性死亡)风险度拉糖肽组低于安慰剂组(HR 0.75,95%CI 0.62-0.92,P=0.004),eGFR年均下降斜率度拉糖肽组小于安慰剂组(-1.37 vs -1.56 mL/min/1.73 m2/年,P<0.001)。

要点

  • 度拉糖肽组肾脏功能相关复合结局风险低于安慰剂组,HR 0.75(95%CI 0.62-0.92,P=0.004)。
  • eGFR持续下降≥40%的风险度拉糖肽组低于安慰剂组,HR 0.72(95%CI 0.58-0.88,P=0.002)。
  • eGFR年均下降斜率度拉糖肽组-1.37 vs 安慰剂组-1.56 mL/min/1.73 m2/年,P<0.001。

核心结论

  • 度拉糖肽组肾脏功能相关结局的估计风险降低25%,提示其可能延迟或减缓2型糖尿病患者糖尿病肾脏疾病的发生发展。

研究设计与样本

  • REWIND试验的探索性事后分析,意向性治疗分析纳入度拉糖肽1.5 mg组4949例和安慰剂组4952例2型糖尿病伴既往心血管疾病或心血管危险因素者。
  • 评估肾脏功能相关复合结局(eGFR持续下降≥40%、终末期肾病或肾性死亡)发生时间及eGFR年均斜率,整体及按基线UACR(<30或≥30 mg/g)和基线eGFR(<60或≥60 mL/min/1.73 m2)亚组分析。

主要发现

  • 肾脏功能相关复合结局度拉糖肽组发生率低于安慰剂组(HR 0.75,95%CI 0.62-0.92,P=0.004),按UACR或eGFR亚组未见度拉糖肽疗效差异的证据。
  • eGFR持续下降≥40%度拉糖肽组发生率低于安慰剂组(HR 0.72,95%CI 0.58-0.88,P=0.002)。
  • eGFR年均下降斜率度拉糖肽组-1.37 vs 安慰剂组-1.56 mL/min/1.73 m2/年(P<0.001),所有亚组结果相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dulaglutide (DU) 1.5 mg was associated with improved composite renal outcomes that included new-onset macroalbuminuria in people with type 2 diabetes with previous cardiovascular disease or cardiovascular risk factors in the REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial. This exploratory post hoc analysis evaluated kidney function-related outcomes, excluding the new-onset macroalbuminuria component, among the REWIND participants. RESEARCH DESIGN AND METHODS: Intent-to-treat analyses were performed on REWIND participants (n = 4,949 DU, n = 4,952 placebo). Time to occurrence of a composite kidney function-related outcome (≥40% sustained decline in estimated glomerular filtration rate [eGFR], per the Chronic Kidney Disease Epidemiology Collaboration 2009 equation, end-stage renal disease, or renal-related death), and mean annual eGFR slope were examined. Analyses were conducted overall and within subgroups defined by baseline urinary albumin-to-creatinine ratio (UACR <30 or ≥30 mg/g) and baseline eGFR (<60 or ≥60 mL/min/1.73 m2). RESULTS: The post hoc composite kidney function-related outcome occurred less frequently among participants assigned to DU than placebo (hazard ratio [HR] 0.75, 95% CI 0.62-0.92, P = 0.004), with no evidence of a differential DU treatment effect by UACR or eGFR subgroup. A ≥40% sustained eGFR decline occurred less frequently among participants assigned to DU than placebo (HR 0.72, 95% CI 0.58-0.88, P = 0.002). The mean annual decline in eGFR slope was significantly smaller for participants assigned to DU than placebo (-1.37 vs. -1.56 mL/min/1.73 m2/year, P < 0.001); results were similar for all subgroups. CONCLUSIONS: The estimated 25% reduced hazard of a kidney function-related outcome among participants assigned to DU highlights its potential for delaying or slowing the development of diabetic kidney disease in people with type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Botros FT, Gerstein HC, Malik R, et al. Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. Diabetes Care. 2023. PMID: 37343574. doi:10.2337/dc23-0231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。